Most Read Articles
Tristan Manalac, 25 Jan 2020
Unusual involvement of the eyes with atypical presentations may occur in patients with inflammatory bowel diseases (IBD) on antitumour necrosis factor (anti-TNF) therapy, according to a recent study presented at the 2019 Advances in Inflammatory Bowel Diseases Annual Meeting (AIBD 2019).

Diabetic retinopathy risk in T2D exacerbated by postprandial hyperglycaemia

21 Jan 2020

Postprandial hyperglycaemia may increase the risk of incident diabetic retinopathy (DR) in patients with type 2 diabetes (T2D) independently of glycated haemoglobin (HbA1c) status, reports a new study.

Researchers enrolled patients with measurements for intrapersonal mean blood glucose levels 1–2 hours postbreakfast (1–2h-PBBG; n=323), postlunch (1–2h-PLBG; n=406) and both (1–2h-PBLBG; n=487). Data were collected over the first 2 years of their clinical follow-ups. The incidence of mild-to-moderate nonproliferative DR was the study endpoint.

A total of 145, 92 and 126 participants in the PBLBG, PBBG and PLBG groups developed incident DR, respectively. The corresponding median follow-up times for these groups were 6.9, 7.5 and 6.7 years.

Multivariate Cox proportional hazards analysis found that when taken as continuous variables, the mean 1–2h-PBLBG (hazard ratio [HR], 1.08, 95 percent confidence interval [CI], 1.01–1.17; p=0.033), PBBG (HR, 1.08, 95 percent CI, 1.00–1.17; p=0.047) and PLBG (HR, 1.07, 95 percent CI, 1.01–1.13; p=0.026) were all significantly predictive of DR development.

In all three cases, HbA1c level likewise emerged as a significant risk factor for DR (PBLBG: HR, 1.70, 95 percent CI, 1.28–2.26; p=0.0003; PBBG: HR, 1.73, 95 percent CI, 1.17–2.56; p=0.006; PLBG: HR, 1.71, 95 percent CI, 1.29–2.29; p=0.0002). However, HbA1c did not seem to be a significant modifier for the effect of postprandial glycaemia on DR risk.

“Even with well-controlled HbA1c levels, correcting postprandial hyperglycaemia is important for preventing DR, especially in middle-aged adults with T2D,” said researchers.

Editor's Recommendations
Most Read Articles
Tristan Manalac, 25 Jan 2020
Unusual involvement of the eyes with atypical presentations may occur in patients with inflammatory bowel diseases (IBD) on antitumour necrosis factor (anti-TNF) therapy, according to a recent study presented at the 2019 Advances in Inflammatory Bowel Diseases Annual Meeting (AIBD 2019).